抗SARS-CoV-2疫苗后免疫介导炎症性疾病:新诊断与疾病复发
本研究回顾性分析了2021年2月至2022年2月间在本机构就诊、且在末次抗SARS-CoV-2疫苗接种后30天内有临床表现的153例患者。其中108例既往无免疫介导炎症性疾病(IMID)者中33例(30%)为新发IMID,45例既往有IMID者中69%因疾病复发就诊。作者指出疫苗接种后监测仍在进行,疫苗与新发/复发IMID的因果关系尚待阐明。
要点
- 接种后30天内新发IMID以心包炎、风湿性多肌痛和血管炎最常见。
- 既往有IMID者中69%因疾病复发转诊。
- IMID复发者合并症更少且倾向于更年轻。
核心结论
- 本文回顾性描述了抗SARS-CoV-2疫苗任何剂量后30天内出现新发IMID或已知IMID复发的患者队列,疫苗与新发/复发IMID的因果关系尚待阐明。
研究设计与样本
- 回顾性队列研究,评估2021年2月至2022年2月间本机构所有有临床表现的住院和门诊患者病历。
- 纳入末次抗SARS-CoV-2疫苗剂量后30天内的153例患者,按预定标准分为既往有或无IMID。
- 记录新发IMID或已知IMID复发,并分析其与人口学、临床和血清学变量的关系。
主要发现
- 153例中45例(29%)既往已诊断IMID,108例(71%)既往无IMID诊断。
- 108例既往无IMID者中33例(30%)诊断为新发IMID,最常见者为心包炎、风湿性多肌痛和血管炎。
- 45例既往有IMID者中,69%因疾病复发转诊。
- 与接种后出现其他情况者相比,IMID复发者合并症数量更少且倾向于更年轻。
局限性
- 本文为回顾性概述。
- 作者指出疫苗接种后监测仍在进行,希望不久能阐明疫苗与新发/复发IMID之间是否存在因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: New-onset immune-mediated inflammatory diseases (IMIDs) and flares of pre-existing IMIDs have been reported following anti- SARS-CoV2 vaccination. Our study aimed at describing a retrospective cohort of patients developing new-onset IMIDs or flares of known IMIDs within 30 days after any anti-SARS-CoV2 vaccine dose. METHODS: We evaluated clinical records of all inpatients and outpatients referring to our institution between February 2021 and February 2022 with any clinical manifestations. We then selected those having received any anti-SARS-CoV2 vaccine dose within the prior 30 days and classified them as having or not a previous IMID according to predefined criteria. We recorded new-onset IMIDs or flares of known IMIDs and investigated any relationship with demographic, clinical and serological variables. RESULTS: 153 patients that received any anti-SARS-CoV2 vaccine dose within the previous 30 days were included of which 45 (29%) already had a diagnosis of IMID while 108 (71%) had no previously diagnosed IMID. 33 (30%) of the 108 patients, were diagnosed with a new-onset IMID. Pericarditis, polymyalgia rheumatica and vasculitis were the most frequent conditions. Among the 45 patients that already had an IMID, disease flare was the reason for referral in 69% of patients. Patients with an IMID flare had a lower number of comorbidities and tended to be younger compared with those who developed other conditions after anti-SARS-CoV2 vaccination. CONCLUSION: We provided a retrospective overview of a cohort of patients who developed new-onset IMIDs or flares of known IMIDs within 30 days after any dose of anti-SARS-CoV2 vaccine. While vaccination campaigns proceed, postvaccination surveillance programmes are ongoing and hopefully will soon clarify whether a causal relationship between vaccines and new-onset/flares of IMIDs exists.
引用
- Carubbi F, Alunno A, Santilli J, et al. Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares. RMD Open. 2022. PMID: 36282905. doi:10.1136/rmdopen-2022-002460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。